A Study of Carbon-14-Labelled [14C] LY3871801 in Healthy Male Participants

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

8 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-09-15

Study Completion Date

2023-11-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of this study is to evaluate how much of the study drug (LY3871801), administered as a single dose that has the radioactive substance 14C incorporated into it, passes from blood into urine, feces and expired air in healthy male participants. The study will also measure how much of the study drug gets into the bloodstream, how its broken down, and how long it takes the body to get rid of it. The study will last up to approximately 9 weeks including the screening period.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Carbon-14-Labelled [14C] LY3372689 in Healthy Male Participants

NCT05749848

Healthy

COMPLETED PHASE1

A Study of Carbon-14-Labelled [14C] LY3556050 in Healthy Male Participants

NCT06052462

Healthy

COMPLETED PHASE1

A Study of Carbon-14-Labelled [14C] LY3473329 in Healthy Male Participants

NCT06342596

Healthy

COMPLETED PHASE1

A Study of [¹⁴C]-LY3023414 in Healthy Participants

NCT02575703

Healthy

COMPLETED PHASE1

A Study of How the Body Breaks Down and Eliminates LY2623091

NCT02242981

Healthy Volunteers

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

[14C]-LY3871801

Single dose of \[¹⁴C\]-LY3871801 administered orally

Group Type EXPERIMENTAL

[14C]-LY3871801

Intervention Type DRUG

Administered orally

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

[14C]-LY3871801

Administered orally

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male participants who are overtly healthy as determined by medical evaluation
* Have a body mass index of 18.5 to 32.0 kilograms per meter squared (kg/m²), inclusive
* Males who agree to use highly effective or effective methods of contraception

Exclusion Criteria

* Have known allergies to LY3871801, related compounds, or any components of the formulation, or a history of significant atopy
* Have received or intend to receive any vaccination within 30 days prior to dosing until the follow-up phone call
* Have participated in a radiolabeled drug study, where exposures are known to the investigator or designee, within 4 months prior to check-in, or participated in a radiolabeled drug study, where exposures are not known to the investigator or designee, within 6 months prior to check-in

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes